Cetuximab, a monoclonal antibody inhibiting EGFR, has demonstrated improved survival in HNSCC patients when combined with chemotherapy or radiation, leading to Food and Drug Administration (FDA) approval for these approaches [3–7]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.